Giovanni Morana

Dr. Giovanni Morana

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in JCO Precision Oncology
Verified
Journal Article
Closed access
LNLiana Nobre
Liana Nobre
MZMichal Zapotocky
Michal Zapotocky
VRVijay Ramaswamy
Vijay Ramaswamy
SRScott Ryall
Scott Ryall
JBJulie Bennett
Julie Bennett
UTUri Tabori
Uri Tabori
PURPOSE: Children with pediatric gliomas harboring a BRAF V600E mutation have poor outcomes with current chemoradiotherapy strategies. Our aim was to study the role of targeted BRAF inhibition in these tumors. PATIENTS AND METHODS: We collected clinical, imaging, molecular, and outcome information from patients with BRAF V600E–mutated glioma treated with BRAF inhibition across 29 centers from multiple countries. RESULTS: Sixty-seven patients were treated with BRAF inhibition (pediatric low-grade gliomas [PLGGs], n = 56; pediatric high-grade gliomas [PHGGs], n = 11) for up to 5.6 years. Objective responses were observed in 80% of PLGGs, compared with 28% observed with conventional chemotherapy ( P < .001). These responses were rapid (median, 4 months) and sustained in 86% of tumors up to 5 years while receiving therapy. After discontinuation of BRAF inhibition, 76.5% (13 of 17) of patients with PLGG experienced rapid progression (median, 2.3 months). However, upon rechallenge with BRAF inhibition, 90% achieved an objective response. Poor prognostic factors in conventional therapies, such as concomitant homozygous deletion of CDKN2A, were not associated with lack of response to BRAF inhibition. In contrast, only 36% of those with PHGG responded to BRAF inhibition, with all but one tumor progressing within 18 months. In PLGG, responses translated to 3-year progression-free survival of 49.6% (95% CI, 35.3% to 69.5%) versus 29.8% (95% CI, 20% to 44.4%) for BRAF inhibition versus chemotherapy, respectively ( P = .02). CONCLUSION: Use of BRAF inhibition results in robust and durable responses in BRAF V600E–mutated PLGG. Prospective studies are required to determine long-term survival and functional outcomes with BRAF inhibitor therapy in childhood gliomas.

1 April 2009 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
MGMaria Luisa Garrè
Maria Luisa Garrè
ACArmando Cama
Armando Cama
FBFrancesca Bagnasco
Francesca Bagnasco
GMGiovanni Morana
Giovanni Morana
FGFelice Giangaspero
Felice Giangaspero
TPTorsten Pietsch
Torsten Pietsch
Purpose: We aimed to test the hypothesis that medulloblastoma (MB) variants show a different age distribution and clinical behavior reflecting their specific biology, and that MB occurring at very young age is associated with cancer predisposition syndromes such as Gorlin syndrome (GS). Experimental Design: We investigated the frequency, age distribution, location, response to treatment, outcome, and association with familial cancer predisposition syndromes in a series of 82 cases of MB in patients ages <14 years diagnosed at the Giannina Gaslini Children's Hospital, Genoa, between 1987 and 2004. Results: Desmoplastic MB and MB with extensive nodularity (MBEN), were present in 22 of 82 cases (27%) and were more frequent in children ages ≤3 years (13 of 25; 52%). In this age group, MBEN was significantly more frequent than desmoplastic MB and classic MB (P < 0.001) and had a good prognosis. MBEN was associated with GS in 5 of 12 cases. Overall, 8 cases occurred in the context of familial tumor predisposition syndromes (5 GS, 1 each NF1, Li-Fraumeni, and Fragile X) and 7 of these patients were ages ≤3 years at diagnosis. Desmoplastic histology and a more intensive treatment represented independent favorable prognostic factors in multivariate analysis (P = 0.003 and P = 0.0139, respectively). Metastasis was a predictor of bad outcome (P = 0.0001). Conclusions: Our data indicate that biologically different MB entities warrant risk-adapted treatment and that MBEN is strongly associated with GS. Patients, ages ≤3 years, with MB and their families should be investigated for tumor predisposition syndromes such as GS.

23 August 2013 in The Journal of Maternal-Fetal & Neonatal Medicine
Verified
Journal Article
Closed access
APAlessandro Parodi
Alessandro Parodi
GMGiovanni Morana
Giovanni Morana
MSMaria S. Severino
Maria S. Severino
MMMariya Malova
Mariya Malova
ANAnna R. Natalizia
Anna R. Natalizia
LRLuca A. Ramenghi
Luca A. Ramenghi
To assess diagnostic accuracy of cranial ultrasonography (CUS) in detecting low-grade (i.e. grade I and grade II) germinal matrix hemorrhage-intraventricular hemorrhage (GMH-IVH) in very low birth weight (VLBW) infants. Among VLBW infants who were admitted to Gaslini Children's Hospital neonatal intensive care unit between January and November 2012, patients who underwent both serial CUS since birth and magnetic resonance susceptibility-weighted imaging (SWI) at term-equivalent age were included in this retrospective study. Diagnostic accuracy of CUS in detecting low-grade GMH-IVH was assessed in terms of sensitivity and specificity by comparing it to SWI, which was used as the gold-standard technique. Sixty VLBW infants were included in the study. Sensitivity of CUS in detecting low-grade GMH-IVH was low (60%), whilst specificity was 100%. In the present study, CUS sensitivity in detecting grade I-II GMH-IVH proved to be surprisingly low, in contrast with specificity. In other words, we suggest that low-grade GMH-IVH may be underdiagnosed in VLBW infants when assessed exclusively with CUS.

27 April 2019 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
Arnoldo PiccardoArnoldo Piccardo
Arnoldo Piccardo
DTDomenico Tortora
Domenico Tortora
SMSamantha Mascelli
Samantha Mascelli
MSMariasavina Severino
Mariasavina Severino
GPGianluca Piatelli
Gianluca Piatelli
GMGiovanni Morana
Giovanni Morana

27 September 2017 in European Radiology
Verified
Journal Article
Closed access
PDF file
DTDomenico Tortora
Domenico Tortora
CMCarola Martinetti
Carola Martinetti
MSMariasavina Severino
Mariasavina Severino
SUSara Uccella
Sara Uccella
MMMariya Malova
Mariya Malova
ARAndrea Rossi
Andrea Rossi

10 May 2021 in Child's Nervous System
Verified
Journal Article
Closed access
PDF file
SAShivaram Avula
Shivaram Avula
APAndrew Peet
Andrew Peet
GMGiovanni Morana
Giovanni Morana
PMPaul Morgan
Paul Morgan
MWMonika Warmuth-Metz
Monika Warmuth-Metz
EGEuropean Society for Paediatric Oncology (SIOPE)-Brain Tumour Imaging Group
European Society for Paediatric Oncology (SIOPE)-Brain Tumour Imaging Group